iTMS - Implementing Transcranial Magnetic Stimulation (TMS) to Assess Cortico-spinal Tract Integrity

Sponsor
University of Aarhus (Other)
Overall Status
Recruiting
CT.gov ID
NCT06153017
Collaborator
Hammel Neurocenter University Hospital and Research Clinic (Other)
100
1
29
3.4

Study Details

Study Description

Brief Summary

Reliable prediction of upper limb (UL) function can guide clinicians in choosing relevant treatment, helps to set realistic goals for rehabilitation and will contribute to personalized and effective rehabilitation. TMS has been identified as a strong predictor of future UL function after stroke. With this project, the investigators want to implement the standard use of TMS examination for a defined patient group in the clinical setting and systematically evaluate the implementation process. The impact and perceived value of TMS in the clinical setting will be evaluated and the predictive value of TMS for the specific patient population will be assessed.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Design Design: A prospective longitudinal implementation study. Setting and population: The implementation will take place at Hammel Neurorehabilitation Centre and University Research Clinic. The target population are patients with stroke.

    Management The study will be organized by the Research Unit at Hammel Neurocenter, Iris Brunner, associate professor, PhD, in collaboration with the Center Management represented by head physician Kåre Eg Severinsen, MD, PhD and the unit for professional development, represented by Camilla Biering Lundquist PhD.

    Evaluation of the implementation The RE-AIM framework, and its extension, the Practical Implementation Sustainability Model (PRISM) framework will be applied to guide and evaluate the implementation process. The RE-AIM framework has been used in numerous studies and hosts a homepage with comprehensive online resources for planning, evaluating and reporting implementation studies.

    Briefly, it consists of the following components to evaluate the success of an implementation:

    Reach. Refers to percent of individuals who are reached by the intervention. In the context of the present study, Reach would describe the number of patients for whom the TMS examination would be relevant, and the percentage of patients who received TMS, and reasons for not being examined.

    • Evaluation of Reach through monitoring of 4 selected wards with the help of the Business Intelligence (BI) portal.

    Effectiveness: Entails the measurement of primary and broader outcomes. In this study, Effectiveness would assess the prediction accuracy for the specific population at the hospital.

    • Evaluation of Effectiveness. Fifty patients will be recruited consecutively from all wards at Hammel Neurorehabilitation Center's sites Hammel and Skive. Follow-up assessments of UL function will be conducted at 3 months post-stroke with the tests of UL function described in 3d. It will be assessed if individual predictions based on TMS and clinical tests will reach a specificity of 80% or more. In addition, sensitivity, PPV, NPV and overall accuracy/ CCP including 95% CI will be calculated.

    Adoption. The level of actual uptake of the new intervention. Specifically in this study the number of referrals of relevant patients from different wards. Moreover, the number of involved staff (therapists, MDs) with a positive attitude to the TMS examination.

    • Evaluation of adoption will based on quantitative data from monitoring, questionnaires, and interviews.

    Implementation. Description of the actual resources and cost allocated, intervention fidelity, and acceptance.

    • Implementation is evaluated with regard to intervention fidelity. In this case, can patients be examined with TMS within the planned time after stroke and is the workload for trained examiners distributed as agreed on.

    Maintenance. Measures the long-term attrition to an intervention on an individual and a setting level.

    • Among others, the following questions will be addressed: Are the potential obstacles identified in previous components of reach addressed? Is the rate of patients referred to TMS stable over time? Can examination skills be maintained or is there need for a boost? Has new staff been introduced to perform the TMS procedure? Based on these questions and the feedback from questionnaires and interviews the investigators will continuously respond to threats to maintenance and adapt maintenance strategies accordingly.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    100 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    iTMS - Implementing Transcranial Magnetic Stimulation (TMS) to Assess Cortico-spinal Tract Integrity
    Actual Study Start Date :
    May 1, 2023
    Anticipated Primary Completion Date :
    Dec 31, 2024
    Anticipated Study Completion Date :
    Sep 30, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Action Research Arm Test [3 months after stroke]

      Assesses arm motor function, range 0-57 (best)

    Secondary Outcome Measures

    1. Shoulder Abduction Finger Extension Test [3 months after stroke]

      Assesses impairment for shoulder abduction and finger extension (0-10 best)

    2. Fugl-Meyer Motor Assessment Upper Limb (0-66 best) [3 months after stroke]

      Assesses upper limb motor impairment

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • admitted to rehabilitation within 21 days after stroke

    • severe UL impairment, either paralysis (no active movement), or severe paresis, defined as Fugl-Meyer Assessment <17 or Shoulder Abduction Finger Extension (SAFE) score < 5

    • At least 18 years old

    • able to provide informed consent and comply with examination procedures

    Exclusion Criteria:
    • Epilepsy

    • Metal implants in the head

    • Other implanted electronics (cardiac pacemaker, defibrillator, cochlear implant, medication pump)

    • Skull fracture or serious head injury

    • Pregnancy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hammel Neurorehabilitation Centre and University Research Clinic Hammel Aarhus Denmark 8450

    Sponsors and Collaborators

    • University of Aarhus
    • Hammel Neurocenter University Hospital and Research Clinic

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Iris Charlotte Brunner, PhD, associate professor, University of Aarhus
    ClinicalTrials.gov Identifier:
    NCT06153017
    Other Study ID Numbers:
    • iTMS786101
    First Posted:
    Dec 1, 2023
    Last Update Posted:
    Dec 1, 2023
    Last Verified:
    Nov 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Iris Charlotte Brunner, PhD, associate professor, University of Aarhus
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 1, 2023